Guardant Health delivered a strong start to 2026, outperforming Wall Street’s revenue expectations in Q1 as robust demand across its core oncology, biopharma, and screening segments powered top-line growth. Management attributed performance to accelerating adoption of its Shield colorectal cancer test, broad-based growth in oncology testing volumes, and recent product enhancements. Co-CEO Helmy Eltoukhy highlighted that “our commercial flywheel has achieved a new level of velocity,” pointing to the company surpassing $1 billion in trailing 12-month revenue for the first time.
Is now the time to buy GH? Find out in our full research report (it’s free for active Edge members).
Guardant Health (GH) Q1 CY2026 Highlights:
- Revenue: $301.7 million vs analyst estimates of $278.2 million (48.3% year-on-year growth, 8.4% beat)
- Adjusted EPS: -$0.45 vs analyst estimates of -$0.47 (5% beat)
- Adjusted EBITDA: -$58.89 million (-19.5% margin, flat year on year)
- The company lifted its revenue guidance for the full year to $1.31 billion at the midpoint from $1.27 billion, a 3.6% increase
- Market Capitalization: $13.06 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Guardant Health’s Q1 Earnings Call
- Mark Massaro (BTIG) asked about the drivers behind the Shield volume guidance raise and the impact of the Quest partnership. Co-CEO AmirAli Talasaz explained that multiple factors, including direct-to-consumer marketing and Quest’s launch, contributed to stronger-than-expected March momentum.
- Subhalaxmi Nambi (Guggenheim) questioned the sustainability of Guardant360’s growth. Co-CEO Helmy Eltoukhy attributed continued strength to broader physician adoption and the increasing capabilities of the Smart platform.
- Patrick Donnelly (Citi) inquired about Reveal volume growth and reimbursement catalysts. Eltoukhy highlighted strong adoption in multiple cancer types and noted that MolDx reimbursement decisions could provide significant upside.
- Colleen Babington (Wolfe Research) sought clarification on Shield’s average selling price trends and payer mix. CFO Mike Bell stated that current ASPs are driven by Medicare but are expected to trend lower as commercial volumes grow.
- Sebastian Sandler (JPMorgan) asked about Guardant360 Tissue’s market share gains and pricing impact from platform upgrades. Eltoukhy emphasized sustainable growth, with further ASP upside possible following regulatory approvals for new features.
Catalysts in Upcoming Quarters
Over the next several quarters, the StockStory team will be tracking (1) Shield’s progress in expanding commercial coverage and sustaining high adherence rates, (2) the pace and impact of new product launches and regulatory milestones, particularly in oncology, and (3) the evolution of reimbursement for new indications such as MRD and multi-cancer detection. Execution on commercial investments and laboratory automation will also be important indicators of Guardant’s ability to scale profitably.
Guardant Health currently trades at $97.24, up from $92.26 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
